Name: BIM-IOL System in Open-angle glaucoma or ocular hypertension: Dosage forms and strengths
Published: 2026-09-17T18:17:42-04:00

Components: drug pads, intraocular lens, and injector

“Our first system in development, the Drug Pad-IOL System, leverages the SpyGlass Platform and integrates approved medicines into two drug pads that are fixed to the haptic arms of our single-piece, hydrophobic acrylic IOL.” (opens the source at this quote in a new tab)
“Our first system in development comprises novel drug pads attached to our IOL (Drug Pad-IOL System), both of which are non-bioerodible, meaning that these components do not break down and they retain their structure and shape as the system elutes medicine.” (opens the source at this quote in a new tab)

Pad material, lens specifications, and dimensions

“The studied drug delivery system consists of two silicone molded pads attached to an IOL (defined as the bimatoprost implant system). Each pad sits at the optic–haptic junction, contains a multiyear bimatoprost load, and delivers slow, continuous elution of bimatoprost with a near-zero-order delivery profile.” (opens the source at this quote in a new tab)
“The SpyGlass IOL itself is a monofocal lens made of hydrophobic acrylic material with a UV inhibitor. Available powers range from 10.0 to 32.0 diopters (D). With pads equipped, the overall product measures 6 mm wide and 12.5 mm long (Fig. 1).” (opens the source at this quote in a new tab)

Strength selected for phase 3 (intended commercial dose)

“In July 2025, we initiated two identical, registrational, Phase 3 clinical trials to evaluate the BIM-IOL System with 78 mcg of bimatoprost, which is designed to consistently deliver three years of bimatoprost.” (opens the source at this quote in a new tab)

“The trial compared BIM-IOL System at the intended commercial dose of 78-mcg (N=51), and 39-mcg (N=23) compared to a physician's choice of commercially available monofocal IOLs from Alcon, Bausch + Lomb or Johnson & Johnson with twice-daily administration of timolol eyedrops as the control group (N=30).” (opens the source at this quote in a new tab)

Strengths studied in earlier trials and their correspondence

“Based on our preclinical results, we designed a FIH trial to evaluate the BIM-IOL System with 75 mcg, 150 mcg and 300 mcg of bimatoprost.” (opens the source at this quote in a new tab)
“Based on the results of our FIH trial, we designed a Phase 1/2 trial to evaluate the safety and efficacy of the BIM-IOL System with 39 mcg and 78 mcg of bimatoprost, which are designed to have similar daily release profiles to the 75 and 150 mcg doses in our FIH trial, respectively.” (opens the source at this quote in a new tab)

Total drug content relative to topical bimatoprost

“The BIM-IOL System is designed to consistently deliver three years of IOP-lowering therapy using less bimatoprost than is contained in a 5mL bottle of topical bimatoprost drops.” (opens the source at this quote in a new tab)

Lens optic configurations under development

“While we believe, based on management projections and internal estimates, that 90% of glaucoma patients receive standard monofocal (or single focus) IOLs during cataract surgery, we are designing for a range of optics, including toric IOLs.” (opens the source at this quote in a new tab)

Commercial packaging, storage conditions, and shelf life

No evidence found.